- Home
- NRGV vs TIL Comparison
NRGV vs TIL Comparison
Compare NRGV & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- TIL
- Stock Information
- Founded
- NRGV 2017
- TIL 2018
- Country
- NRGV United States
- TIL United States
- Employees
- NRGV N/A
- TIL N/A
- Industry
- NRGV Industrial Machinery/Components
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- NRGV Miscellaneous
- TIL Health Care
- Exchange
- NRGV Nasdaq
- TIL Nasdaq
- Market Cap
- NRGV 190.1M
- TIL 171.7M
- IPO Year
- NRGV N/A
- TIL 2021
- Fundamental
- Price
- NRGV $0.76
- TIL $13.23
- Analyst Decision
- NRGV Buy
- TIL Buy
- Analyst Count
- NRGV 4
- TIL 5
- Target Price
- NRGV $1.94
- TIL $114.00
- AVG Volume (30 Days)
- NRGV 1.2M
- TIL 179.4K
- Earning Date
- NRGV 05-12-2025
- TIL 05-20-2025
- Dividend Yield
- NRGV N/A
- TIL N/A
- EPS Growth
- NRGV N/A
- TIL N/A
- EPS
- NRGV N/A
- TIL N/A
- Revenue
- NRGV $46,199,000.00
- TIL N/A
- Revenue This Year
- NRGV $416.66
- TIL N/A
- Revenue Next Year
- NRGV $44.89
- TIL N/A
- P/E Ratio
- NRGV N/A
- TIL N/A
- Revenue Growth
- NRGV N/A
- TIL N/A
- 52 Week Low
- NRGV $0.60
- TIL $9.62
- 52 Week High
- NRGV $2.70
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- NRGV 49.52
- TIL 44.22
- Support Level
- NRGV $0.67
- TIL $11.97
- Resistance Level
- NRGV $0.76
- TIL $14.67
- Average True Range (ATR)
- NRGV 0.07
- TIL 2.05
- MACD
- NRGV 0.03
- TIL -0.04
- Stochastic Oscillator
- NRGV 73.56
- TIL 17.87
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.